Memphasys Ltd (MEM) AI Stock Analysis

• Market Cap: AU$9.92M
• Dividend Yield: N/A
• Average Volume (3M): 5.82M
• Price to Earnings (P/E): ―
• Beta (1Y): -0.61
• Revenue Growth: -41.19%
• EPS Growth: 20.93%
• Country: AU
• Employees: 24
• Sector: Healthcare
• Sector Strength: 39
• Industry: Biotechnology
• EPS (TTM): >-0.01
• Shares Outstanding: 1,983,598,100
• 10 Day Avg. Volume: 10,733,247
• 30 Day Avg. Volume: 5,820,782
• PEG Ratio: -0.08
• Price to Book (P/B): 1.77
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -4.05
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 37 Underperform
• Price Target: ―

Memphasys Ltd faces significant financial challenges, including high debt levels and negative profitability, leading to a low financial performance score. The lack of technical data adds uncertainty to market perceptions. Valuation metrics suggest potential if fundamental improvements occur. Overall, the stock is precarious, with substantial risks that need addressing for long-term viability.

Memphasys Ltd Business Overview & Revenue Model

Company Description

Memphasys Ltd (MEM) is an Australian-based biotechnology company specializing in reproductive biotechnology solutions. The company focuses primarily on developing and commercializing innovative products and technologies that enhance the reproductive success in humans and animals. Its flagship product, Felix, is a patented sperm separation device designed to improve the success rates of in vitro fertilization (IVF) by selecting the best quality sperm for use in the process.

How the Company Makes Money

Memphasys Ltd generates revenue primarily through the development and commercialization of its reproductive biotechnology products. The company's key revenue stream is the sales of its Felix device to fertility clinics and medical institutions engaged in IVF treatments. Additionally, Memphasys may pursue partnerships or collaborations with other companies in the biotechnology or medical technology sectors to expand its market reach and enhance product distribution. The company could also earn revenue through licensing agreements and potential future development of other reproductive health technologies.

Memphasys Ltd Financial Statement Overview

Summary

Memphasys Ltd operates in the biotechnology sector, facing consistent profitability and cash flow challenges despite recent revenue growth. The high debt levels and continuous net losses present significant risks, though external financing has temporarily stabilized operations. Improvement in cost management and profitability is essential for long-term sustainability.

Income Statement

Memphasys Ltd has shown some revenue growth, increasing from $15,371 in 2023 to $60,000 in 2024, representing a strong growth rate. However, the company consistently reports negative gross profit, indicating high cost of goods sold relative to revenue. Net profit margins remain negative, driven by substantial net losses, suggesting ongoing profitability challenges.

Balance Sheet

The company maintains a high debt-to-equity ratio indicative of significant leverage, which could pose financial risks. Stockholders' equity has decreased slightly over time. The equity ratio is stable but not high, indicating moderate reliance on equity financing. Overall, the balance sheet reflects a leveraged financial structure with potential risk but some stability in equity.

Cash Flow

Memphasys Ltd's cash flow statement shows negative free cash flow, reflecting operating challenges. Operating cash flow to net income ratio is negative, indicating insufficient cash generation to cover losses. Financing cash flows are positive, highlighting reliance on external financing to support operations.

Breakdown	TTM	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement
Total Revenue	349.34K	60.00K	15.37K	27.15K	211.48K	0.00
Gross Profit	-316.83K	-1.57M	-824.86K	-922.60K	-48.00K	-196.23K
EBITDA	-3.06M	-3.31M	-2.36M	-1.39M	-1.14M	-869.05K
Net Income	-5.11M	-4.44M	-3.40M	-2.08M	-1.49M	-1.13M
Balance Sheet
Total Assets	10.99M	12.43M	14.67M	14.12M	14.58M	11.30M
Cash, Cash Equivalents and Short-Term Investments	516.27K	277.80K	680.58K	311.83K	2.05M	2.01M
Total Debt	4.30M	4.81M	6.37M	5.56M	5.36M	1.04M
Total Liabilities	4.91M	5.59M	7.28M	6.47M	5.97M	1.54M
Stockholders Equity	6.07M	6.84M	7.38M	7.65M	8.61M	9.76M
Cash Flow
Free Cash Flow	-3.12M	-3.87M	-3.23M	-2.61M	-2.96M	-3.02M
Operating Cash Flow	-3.27M	-3.23M	-1.41M	311.82K	47.25K	120.19K
Investing Cash Flow	-274.88K	-711.05K	-1.98M	-3.08M	-3.00M	-3.14M
Financing Cash Flow	4.03M	3.54M	3.75M	1.03M	2.99M	4.11M

Memphasys Ltd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	49 Neutral	AU$2.50B	4.42	-64.25%	2.77%	36.51%	13.14%
1AD	46 Neutral	AU$2.68M	―	-392.18%	―	―	34.26%
AVE	46 Neutral	AU$11.11M	―	-64.72%	―	139.19%	33.33%
CHM	42 Neutral	AU$10.08M	―	-180.09%	―	―	28.57%
MEM	37 Underperform	AU$9.92M	―	-80.47%	―	-41.19%	20.93%

Memphasys Ltd Corporate Events

Memphasys Advances Global Strategy with CE Mark Application for Felix™

Memphasys Limited has submitted a CE Mark application for its Felix™ sperm separation device, marking a significant step in its global commercialization strategy. This milestone is expected to unlock commercial access in the EU and accelerate approvals in other regions, enhancing the company’s market positioning in the rapidly growing IVF sector. The Felix™ device offers a significant reduction in sperm preparation time, which is crucial for improving efficiency in fertility clinics. Memphasys is adopting a direct commercialization approach in markets with lower regulatory requirements, such as Japan, Canada, and New Zealand, to build early momentum and demonstrate the device’s value, while strategic distribution partnerships remain a long-term focus.

Memphasys Appoints Marjan Mikel as Non-Executive Director to Boost Global Expansion

Memphasys Limited has appointed Marjan Mikel as a Non-Executive Director, bringing extensive experience in business development and commercialisation across the Medtech, diagnostics, healthcare services, and life sciences sectors. Mikel’s previous roles and familiarity with Memphasys’ strategic vision are expected to aid the company’s global expansion of its Felix™ system and accelerate the commercialisation of the RoXsta™ platform.

Memphasys Limited Appoints New Auditor Amidst Strategic Commercialization Efforts

Memphasys Limited has announced a change in its external auditors, appointing BDO Audit Pty Ltd following the resignation of Pitcher Partners. This decision comes as part of a corporate review by the Board, aligning with the company’s strategic move towards the international commercialization of its Felix™ Device.

Memphasys Ltd Completes Share Placement

Memphasys Ltd has completed a placement of 212,583,334 ordinary shares at $0.006 per share without disclosure under Part 6D.2 of the Corporations Act. The company has ensured compliance with relevant provisions of the Corporations Act, indicating transparency and adherence to regulatory standards, which may bolster investor confidence.

Memphasys Ltd Announces Quotation of New Securities on ASX

Memphasys Ltd announced the application for quotation of 212,583,334 ordinary fully paid securities on the ASX, issued as part of a previously announced transaction. This move is expected to enhance the company’s market presence and provide additional capital for its operations, potentially impacting its industry positioning and offering new opportunities for stakeholders.

Memphasys Ltd Updates Proposed Securities Issue Dates

Memphasys Ltd has announced an update regarding the proposed issue of securities, with changes to the issue date and option expiry date now set for April 15, 2025, and April 15, 2027, respectively. This update reflects the company’s strategic financial maneuvers to leverage its ASX Listing Rule 7.1 capacity, potentially impacting its market positioning and providing stakeholders with revised timelines for investment opportunities.

Memphasys Secures Funding to Boost Reproductive Biotech Innovations

Memphasys Limited has secured A$1.275 million through a strategic placement to advance the commercialisation of its Felix™ and RoXsta™ systems. The funds will support licensing, joint ventures, and distribution agreements, particularly following successful clinical trial results for the Felix™ System, which demonstrated superior performance to existing sperm preparation methods. The RoXsta™ System is gaining traction in veterinary applications, showing potential for livestock reproductive health and early mastitis detection in dairy cattle.

Memphasys Ltd Announces Proposed Securities Issue

Memphasys Ltd has announced a proposed issue of 212,500,000 new securities, which will be fully paid ordinary shares. This move is part of a placement or other type of issue, with the proposed issue date set for April 11, 2025. This announcement could potentially impact the company’s market positioning by increasing its capital base, which may be used for further business development or operational expansion.